Medigene participates at five upcoming international conferences
(Thomson Reuters ONE) -
Medigene AG /
Medigene participates at five upcoming international conferences
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 3 August 2016. Medigene AG (MDG1, Frankfurt, Prime Standard)
announces its participation at five upcoming science, investment and business
development conferences:
* CAR-TCR Summit
Date: 13 - 15 September 2016
Location: Boston, USA
CEO/CSO Prof. Dolores Schendel will give a talk on 14 September on the topic:
"The ABC's of Adoptive T Cell Therapy Using Optimal-Affinity Natural TCRs
Specific for Hematological Malignancies and Solid Tumors".
* Baader Investment Conference
Date: 20 - 22 September 2016
Location: Munich, Germany
Medigene's Senior Vice President Corporate Development, Dr. Dr. Olav Zilian,
will give a corporate presentation on 21 September.
* Phacilitate Leaders Europe
Date: 21 - 22 September 2016
Location: Berlin, Germany
Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will
present on 22 September 2016 on: "What improvements can second and third
generation CAR and TCR-based immunotherapies offer in terms of both safety and
persistence of response?"
* Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference:
Translating Science into Survival
Date: 25 - 28 September 2016
Location: New York, USA
Medigene will present a poster on 25 and 26 September with the title: "Method
for molecular characterization of antigens, epitopes and T cell receptors for
adoptive CD4 immunotherapy".
* European Business Development Conference
Date: 27 - 28 September 2016
Location: Frankfurt, Germany
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. The company is
developing highly innovative, complementary treatment platforms to target
various types and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T cell-
based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(® )is a registered trademark of Medigene AG. This trademark may be
owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor(at)medigene.com
In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor(at)medigene.com). We will then delete your address
from our distribution list.
Press release English PDF:
http://hugin.info/132073/R/2032662/756687.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#2032662]
Unternehmensinformation / Kurzprofil:
Datum: 03.08.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 486942
Anzahl Zeichen: 3921
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 244 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene participates at five upcoming international conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
